Prostate Cell News Volume 9.05 | Feb 9 2018

TOP STORY

BMI1 Regulates Androgen Receptor in Prostate Cancer Independently of the Polycomb Repressive Complex 1

The authors report a polycomb repressive complex 1-independent role of BMI1 that is critical for castration-resistant prostate cancer progression. BMI1 bound the androgen receptor (AR) and prevented MDM2-mediated AR protein degradation, resulting in sustained AR signaling in prostate cancer cells. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Direct Transfection of Clonal Organoids in Matrigel Microbeads: A Promising Approach toward Organoid-Based Genetic Screens

Scientists developed an innovative approach for transgene expression in 3D organoids by combining single-cell encapsulation in Matrigel microbeads using a microfluidic device and electroporation. They demonstrated that direct electroporation of encapsulated organoids reaches up to 80% of transfection efficiency. [Nucleic Acids Res] Full Article

Extracellular Redox State Shift: A Novel Approach to Target Prostate Cancer Invasion

Altered expression of extracellular superoxide dismutase (ECSOD) and glutamate transporter (xCT) can lead to imbalance of the tumor microenvironment redox state and likely have a profound effect on cancer invasion. The authors investigated whether ECSOD and xCT could be therapeutic targets for prostate cancer invasion. [Free Radic Biol Med] Abstract

LanCL1 Protects Prostate Cancer Cells from Oxidative Stress via Suppression of JNK Pathway

Lanthionine synthase C-like protein 1 (LanCL1) promoted prostate cancer cell proliferation and helped protect cells from damage caused by oxidative stress. Suppression of LanCL1 by siRNA resulted in increased cancer cell apoptosis. [Cell Death Dis] Full Article

MicroRNA-27a-5p Regulation by Promoter Methylation and MYC Signaling in Prostate Carcinogenesis

Scientists elucidated the role of regulatory network between MYC and miRNAs in prostate carcinogenesis. MYC expression was found upregulated in prostate cancer cases and matched precursor lesions. [Cell Death Dis] Full Article

Differential Gene Expression Induced by Anti-Cancer Agent Plumbagin Is Mediated by Androgen Receptor in Prostate Cancer Cells

Researchers performed RNA-seq analysis on cells treated with combinations of plumbagin and dihydrotestosterone, and analyzed differential gene expression, to gain insight into the interactions between androgen and plumbgin. [Sci Rep] Full Article

ITGB1-Dependent Upregulation of Caveolin-1 Switches Tgfβ Signaling from Tumor-Suppressive to Oncogenic in Prostate Cancer

The authors suggested TGFβ signaling and beta1 integrins as potential therapeutic targets in prostate cancer over-expressing caveolin-1. [Sci Rep] Full Article

Veterinary Drug, 17β-Trenbolone Promotes the Proliferation of Human Prostate Cancer Cell Line through the Akt/AR Signaling Pathway

Researchers found that 17β-trenbolone induces androgen receptor-dependent cell proliferation in the human prostate cancer cell line, 22Rv1 in a concentration dependent manner. [Chemosphere] Abstract

SIRT3 Inhibits Prostate Cancer Metastasis through Regulation of FOXO3A by Suppressing Wnt/β-Catenin Pathway

Investigators reported that SIRT3 inhibited the epithelial-mesenchymal transition and migration of prostatic cancer cells in vitro and their metastasis in vivo. [Exp Cell Res] Abstract

Nc886 Is Epigenetically Repressed in Prostate Cancer and Acts as a Tumor Suppressor through the Inhibition of Cell Growth

Nc886 promoter methylation increased in tumor vs. normal prostate tissue, as well as in metastatic vs. normal prostate tissue. Additionally, nc886 promoter methylation correlated with prostate cancer clinical staging, including biochemical recurrence, Clinical T-value and Gleason score. [BMC Cancer] Full Article

Integrin Inhibitors in Prostate Cancer

Scientists review the role of integrins inhibitors in prostate cancer (PCa) and their potential as therapeutic targets for PCa treatments. [Cancers] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate Cancer

Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy. The results of a multi-institutional, Phase III clinical trial of apalutamide – led by investigators from Massachusetts General Hospital and University of California, San Francisco – are receiving early release publication in the New England Journal of Medicine to coincide with a presentation. [Press release from Massachusetts General Hospital discussing research presented at American Society for Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium, San Francisco] Press Release | Abstract

Phase III Prosper Trial Shows XTANDI^® (Enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. and Pfizer Inc. announced results from the Phase III PROSPER trial in patients with non-metastatic castration-resistant prostate cancer. [Pfizer Inc.] Press Release

ERLEADA^™ (Apalutamide), A Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new findings from the Phase III SPARTAN clinical trial that showed treatment with ERLEADA^™, an investigational, next-generation androgen receptor inhibitor, decreased risk of metastasis or death by 72% and improved median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer whose prostate specific antigen is rapidly rising, compared to placebo. [The Janssen Pharmaceutical Companies of Johnson & Johnson] Press Release

ZYTIGA^® (Abiraterone Acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the FDA has approved a new indication for ZYTIGA^® in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer. [The Janssen Pharmaceutical Companies of Johnson & Johnson] Press Release

With $3.1M Grant from NIH, UCLA Scientists to Advance Adoption of Focal Therapy to Treat Prostate Cancer

University of California, Los Angeles researchers Dr. Leonard Marks and Shyam Natarajan will lead a $3.1 million research project grant awarded by the National Institutes of Health to advance the adoption of a promising new technology to treat men with prostate cancer. [University of California, Los Angeles] Press Release

New U.S. Budget Deal Includes More Funding for 2020 Census

The latest short-term budget agreement that keeps the U.S. government running for another six weeks gives a much-needed boost to planning for the 2020 census. [ScienceInsider] Editorial

NSF Requires Institutions to Report Sexual Harassment Findings

The National Science Foundation (NSF) in Alexandria, Virginia, announced a new set of measures to combat sexual harassment by people working on the projects it funds. The steps may include suspending or eliminating research grants after an institution finds that a grantee committed harassment. [ScienceInsider] Editorial

Breakthrough in Budget Negotiations Could Raise Spending for Science

Top lawmakers in Congress announced a budget agreement that could produce substantial spending increases for research at key U.S. science agencies-and avoid a partial government shutdown. But the deal must still clear a few hurdles before it is finalized. [ScienceInsider] Editorial

NEW The New York Stem Cell Foundation (NYSCF) Conference 2018
October 23-24, 2018
New York, New York, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Scientist Opportunities – Biomedical Research (Cedars-Sinai)

NEW Postdoctoral Fellow – Prostate Disease Research (Henry M. Jackson Foundation for the Advancement of Military Medicine)

NEW Postdoctoral Scientist – Cancer Research (Boehringer Ingelheim)

Postdoctoral Fellow – Cancer Biology (Johns Hopkins University)

Scientist – Cancer Biology (Dana-Farber Cancer Institute)

Postdoctoral Research Fellow – Nuclear and Mitochondrial Mutagenesis in Carcinogenesis (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Cancer Biology (University of Pennsylvania)

Postdoctoral Fellow – Cancer Biology (Wake Forest Baptist Comprehensive Cancer Center)

Professor, Tenure Canada Excellence Research Chair – Precision Cancer Drug Design (University of British Columbia)

Assistant Professor, Associate Professor & Professor – Cell & Molecular Biology (University of Mississippi)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.